health
Bayer aims to increase operating margin in pharmaceuticals to around 30 percent
German pharmaceutical and agrochemical giant Bayer today confirmed its long-term growth targets in the pharmaceutical part of its business, with a plan to increase its operating margin to around 30 percent by 2030.
TL;DR
- Bayer aims for an operating margin of around 30 percent in its pharmaceutical business by 2030.
- Annual revenue growth of 4-6% is expected to resume from 2027.
- Five new drugs are identified as key growth drivers: Asundexian, Nubeqa, Kerendia, Beyonttra, and Lynkuet.
- Pharmaceutical segment revenues slightly fell by 1.7% in 2025 to 17.83 billion euros, but showed a 1.7% increase excluding currency effects.
- The company plans to leverage AI to boost productivity and speed up innovation.
- Bayer achieved a record number of new drug approvals and successful clinical studies last year.
- Productivity in research and development is targeted for a 40% increase by 2030.